METHODS AND COMPOSITIONS FOR TREATING CANCER
DUX4 can be used as a biomarker for predicting a patient's response to immunotherapy, and inhibition of DUX4 can be used in therapeutic methods for treating DUX4+ cancers. Accordingly, aspects of the disclosure relate to a method for treating cancer in a patient comprising administering a DUX4 inhibitor to the patient. Further aspects of the disclosure relate to a method for treating a DUX4+ cancer in a patient, the method comprising administering a checkpoint inhibitor to the patient. Other aspects relate to a composition comprising a DUX4 inhibitor and a checkpoint inhibitor.
1 . A method for treating cancer in a patient, wherein the cancer comprises DUX+ cancer cells, the method comprising administering a therapeutically effective amount of a DUX4 inhibitor to the patient.
2 . (canceled)
3 . The method of claim 1 , wherein the DUX4 inhibitor comprises an antisense oligonucleotide, small interfering RNA (siRNA), short hairpin RNA (shRNA), double-stranded RNA, an antisense oligonucleotide, a ribozyme, or combinations thereof.
4 . (canceled)
5 . The method of claim 1 , wherein the DUX4 is a molecular inhibitor selected from a Bromodomain and Extra-Terminal motif (BET) inhibitor, a CDK7 inhibitor, a Wnt pathway agonist, a beta-2 adrenergic receptor agonist, a p38 inhibitor, a phosphodiesterase (PDE) inhibitor, a cAMP analog, and combinations thereof.
6 . (canceled)
7 . The method of claim 5 , wherein the DUX4 inhibitor comprises a BET inhibitor selected from JQ1, PFI-1, I-BET-762, I-BET-151, RVX-208, CPI-0610, and combinations thereof.
8 . The method of claim 5 , wherein the DUX4 inhibitor comprises a beta-2 adrenergic agonist selected from formoterol, albuterol, CGP20712, CI118,551, clenbuterol, and combinations thereof.
9 . The method of claim 5 , wherein the DUX4 inhibitor comprises a PDE inhibitor selected from ibudilast, crisaborole, and combinations thereof.
10 . The method of claim 1 , wherein the DUX4 inhibitor comprises 8-Bromoadenosine 3′,5′-cyclic monophosphate, a DUX4-s polypeptide, or protein kinase A.
11 - 12 . (canceled)
13 . The method of claim 1 , wherein the cancer comprises cutaneous squamous-cell carcinoma, non-colorectal and colorectal gastrointestinal cancer, Merkel-cell carcinoma, anal cancer, cervical cancer, hepatocellular cancer, urothelial cancer, melanoma, lung cancer, non-small cell lung cancer, small cell lung cancer, head and neck cancer, kidney cancer, bladder cancer, Hodgkin's lymphoma, pancreatic cancer, or skin cancer.
14 - 19 . (canceled)
20 . The method of claim 1 , wherein the method further comprises determining the level of expression of DUX4 or a DUX4-regulated gene in a sample from the patient.
21 . (canceled)
22 . (canceled)
23 . The method of claim 1 , wherein the patient has been previously treated with a prior cancer therapy and wherein the patient was determined to be resistant, poorly responsive, or non-responsive to the prior cancer therapy.
24 - 25 . (canceled)
26 . The method of claim 1 , wherein the method further comprises administration of an additional cancer therapy prior to, after, or concurrently with the DUX4 inhibitor.
27 . The method of claim 26 , wherein the additional therapy comprises chemotherapy, radiation, surgery, or immunotherapy.
28 . (canceled)
29 . The method of claim 27 , wherein the immunotherapy comprises a checkpoint inhibitor therapy.
30 . The method of claim 29 , wherein the checkpoint inhibitor therapy comprises administering a checkpoint inhibitor selected from an antagonist of CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, VISTA, TIGIT, IDO1, or combinations thereof.
31 . The method of claim 29 , wherein the checkpoint inhibitor therapy comprises administering a checkpoint inhibitor selected from Ipilmumab, Nivolumab, Pembrolizumab, BMS-936559, MSB0010718C, MPDL3280A, MedI-4736, pidilizumab, AMP-224, RG7446, Atezolizumab, Ipilimumab, Durvalumab, LY3321367 MBG453, TSR-022, JNJ-61610588, and combinations thereof.
32 . The method of claim 1 , wherein the cancer comprises a solid tumor that comprises DUX4+ cancer cells on the periphery of the solid tumor.
33 . (canceled)
34 . A method for treating a DUX4+ cancer in a patient, the method comprising administering a checkpoint inhibitor to the patient and administering a DUX4 inhibitor prior to, after, or concurrently with the checkpoint inhibitor.
35 . (canceled)
36 . The method of claim 34 , wherein the DUX4 inhibitor comprises a nucleic acid inhibitor, an antibody, or a molecular inhibitor, wherein the DUX4 inhibitor comprises a nucleic acid inhibitor selected from an antisense oligonucleotide, small interfering RNA (siRNA), short hairpin RNA (shRNA), double-stranded RNA, an antisense oligonucleotide, a ribozyme, and combinations thereof, and wherein the DUX4 molecular inhibitor is selected from a Bromodomain and Extra-Terminal motif (BET) inhibitor, a CDK7 inhibitor, a Wnt pathway agonist, a beta-2 adrenergic receptor agonist, a phosphodiesterase (PDE) inhibitor, a cAMP analog, and combinations thereof.
37 - 59 . (canceled)
60 . The method of claim 34 , wherein the checkpoint inhibitor is selected from an antagonist of CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, VISTA, TIGIT, IDO1, or combinations thereof.
61 . The method of claim 60 , wherein the checkpoint inhibitor is selected from selected from Ipilmumab, Nivolumab, Pembrolizumab, BMS-936559, MSB0010718C, MPDL3280A, MedI-4736, pidilizumab, AMP-224, RG7446, Atezolizumab, Ipilimumab, Durvalumab, LY3321367 MBG453, TSR-022, JNJ-61610588, and combinations thereof.
62 - 63 . (canceled)
64 . A composition comprising a DUX4 inhibitor and a checkpoint inhibitor.
65 - 78 . (canceled)